1
|
Boutin A, Gouin S, Bailey B, Lebel D, Gravel J. Additive Value of Intranasal Fentanyl on Ibuprofen for Pain Management of Children With Moderate to Severe Headaches: A Randomized Controlled Trial. J Emerg Med 2023; 65:e119-e131. [PMID: 37474344 DOI: 10.1016/j.jemermed.2023.04.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2022] [Revised: 03/20/2023] [Accepted: 04/19/2023] [Indexed: 07/22/2023]
Abstract
BACKGROUND Few studies have evaluated the rapid pain improvement provided by medications for children presenting to an emergency department (ED) with headaches. OBJECTIVE Our aim was to evaluate pain reduction provided by intranasal fentanyl (INF) compared with placebo in addition to ibuprofen. METHODS A single-center, double-blinded, randomized, placebo-controlled clinical trial was conducted in a tertiary care pediatric ED. All children aged 8-17 years presenting with a moderate to severe headache were eligible. Study participants were randomly allocated to receive INF 1.5 µg/kg (maximum dose of 100 µg) or similar placebo solution. Co-administration of oral ibuprofen 10 mg/kg (maximum dose of 600 mg) was also provided. The primary outcome was the mean pain rating reduction at 15 min. RESULTS Among the 62 participants, the median age was 14 years (interquartile range [IQR] 12-16 years in both groups) and the median initial visual analog scale (VAS) score was 64 (IQR 55-72 in the intervention group; IQR 50-81 in the control group). There was no difference in the mean pain score reduction at 15 min between the two groups (mean difference 2 mm; 95% CI -7 to 11 mm). Mean VAS score reductions were also similar at 30 and 60 min. Adverse events were more frequent in the INF group (risk ratio 2.8; 95% CI 1.29 to 6.22), but all events were minor and transient. No significant differences were found in other outcomes. CONCLUSIONS This study did not find a benefit from INF for providing additional pain relief in children presenting to ED with headaches.
Collapse
Affiliation(s)
- Ariane Boutin
- Department of Pediatric Emergency Medicine, Centre Hospitalier Universitaire Sainte-Justine, Université de Montréal, Montreal, Quebec, Canada.
| | - Serge Gouin
- Department of Pediatric Emergency Medicine, Centre Hospitalier Universitaire Sainte-Justine, Université de Montréal, Montreal, Quebec, Canada
| | - Benoit Bailey
- Department of Pediatric Emergency Medicine, Centre Hospitalier Universitaire Sainte-Justine, Université de Montréal, Montreal, Quebec, Canada
| | - Denis Lebel
- Department of Pharmacy, Centre Hospitalier Universitaire Sainte-Justine, Université de Montréal, Montreal, Quebec, Canada
| | - Jocelyn Gravel
- Department of Pediatric Emergency Medicine, Centre Hospitalier Universitaire Sainte-Justine, Université de Montréal, Montreal, Quebec, Canada
| |
Collapse
|
2
|
Ezzati A, Buse DC, Fanning KM, Reed ML, Martin VT, Lipton RB. Predictors of treatment-response to Acute Prescription Medications in Migraine: Results from the American Migraine Prevalence and Prevention (AMPP) Study. Clin Neurol Neurosurg 2022; 223:107511. [DOI: 10.1016/j.clineuro.2022.107511] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2022] [Revised: 10/21/2022] [Accepted: 11/02/2022] [Indexed: 11/06/2022]
|
3
|
Catapano JS, Karahalios K, Srinivasan VM, Baranoski JF, Rutledge C, Cole TS, Ducruet AF, Albuquerque FC, Jadhav AP. Chronic headaches and middle meningeal artery embolization. J Neurointerv Surg 2021; 14:301-303. [PMID: 33888570 DOI: 10.1136/neurintsurg-2021-017602] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2021] [Revised: 04/07/2021] [Accepted: 04/08/2021] [Indexed: 01/06/2023]
Abstract
BACKGROUND The middle meningeal artery (MMA) has been implicated in chronic headaches, but no studies have examined the relationship between MMA embolization and headaches. METHODS Patients treated with MMA embolization for a chronic subdural hematoma (cSDH) between January 1, 2018, and December 31, 2020, were retrospectively assessed. Patients with a Glasgow Coma Scale (GCS) score of 15 at discharge received a follow-up telephone call to assess their history of chronic headache, defined as a headache ≥2 years before the cSDH and symptoms ≥2 days/month. A Headache Impact Test (HIT-6) was performed during the follow-up telephone call. The primary outcome was resolution or improvement of headaches after embolization. RESULTS Of 76 patients undergoing MMA embolization for a cSDH during the study period, 56 (74%) had a discharge GCS score of 15. Of these 56 patients, 46 (82%) responded to a follow-up telephone call and were analyzed (mean [SD] age 68 [11] years; 36 [78%] men and 10 [22%] women). Nine (20%) reported chronic headaches before embolization. With a mean (SD) follow-up of 489 (173) days, eight of the nine patients reported improvement of chronic headaches, with seven having complete resolution. For these nine patients, the mean (SD) HIT-6 score was significantly higher before embolization than after embolization (64 [7.1] vs 40 [9.1], p<0.001). CONCLUSION In patients with chronic headaches who underwent MMA embolization for a cSDH, the majority reported improvement of headaches after the procedure. Future prospective studies are warranted to assess the usefulness of MMA embolization to treat chronic headaches.
Collapse
Affiliation(s)
- Joshua S Catapano
- Department of Neurosurgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA
| | - Katherine Karahalios
- Department of Neurosurgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA
| | - Visish M Srinivasan
- Department of Neurosurgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA
| | - Jacob F Baranoski
- Department of Neurosurgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA
| | - Caleb Rutledge
- Department of Neurosurgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA
| | - Tyler S Cole
- Department of Neurosurgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA
| | - Andrew F Ducruet
- Department of Neurosurgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA
| | - Felipe C Albuquerque
- Department of Neurosurgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA
| | - Ashutosh P Jadhav
- Department of Neurosurgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA
| |
Collapse
|
4
|
Lipton RB, Buse DC, Friedman BW, Feder L, Adams AM, Fanning KM, Reed ML, Schwedt TJ. Characterizing opioid use in a US population with migraine: Results from the CaMEO study. Neurology 2020; 95:e457-e468. [PMID: 32527971 PMCID: PMC7455347 DOI: 10.1212/wnl.0000000000009324] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2019] [Accepted: 11/07/2019] [Indexed: 01/20/2023] Open
Abstract
Objective To determine the prevalence of and risk factors associated with opioid use in the treatment of migraine, we examined demographics and clinical characteristics of 867 individuals who reported using opioids for the treatment of migraine. Methods We analyzed data from the CaMEO study (Chronic Migraine Epidemiology and Outcomes), a cross-sectional, longitudinal, Internet study, to compare sociodemographics, clinical characteristics, and migraine burden/disability of opioid users vs nonusers. Covariates were entered as categorical or continuous variables. Factors associated with opioid use were identified using nested, multivariable binary logistic regression models. Results Of 2,388 respondents with migraine using prescription medications for acute treatment, 36.3% reported that they currently used or kept on hand opioid medications to treat headaches. Current opioid users had significantly more comorbidities, greater headache-related burden, and poorer quality of life than nonusers. Regression models revealed factors significantly associated with opioid use, including male sex, body mass index, allodynia, increasing monthly headache frequency, Total Pain Index score (excluding head, face, neck/shoulder), anxiety, depression, ≥1 cardiovascular comorbidity, and emergency department/urgent care use for headache in the past 6 months. Self-reported physician-diagnosed migraine/chronic migraine was associated with significantly decreased likelihood of opioid use. Conclusions Of respondents who were using acute prescription medications for migraine, more than one-third used or kept opioids on hand, contrary to guidance. This analysis could not distinguish risk factors from consequences of opioid use; thus further research is needed to guide the development of strategies for reducing the inappropriate use of opioids in migraine.
Collapse
Affiliation(s)
- Richard B Lipton
- From the Department of Neurology (R.B.L., D.C.B., B.W.F.), Albert Einstein College of Medicine, Bronx, NY; Peloton Advantage, LLC, an OPEN Health Company (L.F.), Parsippany, NJ; Global Medical Affairs (A.M.A.), Allergan plc, Irvine, CA; Vedanta Research (K.M.F., M.L.R.), Chapel Hill, NC; and Neurology Research (T.J.S.), Mayo Clinic, Phoenix, AZ.
| | - Dawn C Buse
- From the Department of Neurology (R.B.L., D.C.B., B.W.F.), Albert Einstein College of Medicine, Bronx, NY; Peloton Advantage, LLC, an OPEN Health Company (L.F.), Parsippany, NJ; Global Medical Affairs (A.M.A.), Allergan plc, Irvine, CA; Vedanta Research (K.M.F., M.L.R.), Chapel Hill, NC; and Neurology Research (T.J.S.), Mayo Clinic, Phoenix, AZ
| | - Benjamin W Friedman
- From the Department of Neurology (R.B.L., D.C.B., B.W.F.), Albert Einstein College of Medicine, Bronx, NY; Peloton Advantage, LLC, an OPEN Health Company (L.F.), Parsippany, NJ; Global Medical Affairs (A.M.A.), Allergan plc, Irvine, CA; Vedanta Research (K.M.F., M.L.R.), Chapel Hill, NC; and Neurology Research (T.J.S.), Mayo Clinic, Phoenix, AZ
| | - Lisa Feder
- From the Department of Neurology (R.B.L., D.C.B., B.W.F.), Albert Einstein College of Medicine, Bronx, NY; Peloton Advantage, LLC, an OPEN Health Company (L.F.), Parsippany, NJ; Global Medical Affairs (A.M.A.), Allergan plc, Irvine, CA; Vedanta Research (K.M.F., M.L.R.), Chapel Hill, NC; and Neurology Research (T.J.S.), Mayo Clinic, Phoenix, AZ
| | - Aubrey Manack Adams
- From the Department of Neurology (R.B.L., D.C.B., B.W.F.), Albert Einstein College of Medicine, Bronx, NY; Peloton Advantage, LLC, an OPEN Health Company (L.F.), Parsippany, NJ; Global Medical Affairs (A.M.A.), Allergan plc, Irvine, CA; Vedanta Research (K.M.F., M.L.R.), Chapel Hill, NC; and Neurology Research (T.J.S.), Mayo Clinic, Phoenix, AZ
| | - Kristina M Fanning
- From the Department of Neurology (R.B.L., D.C.B., B.W.F.), Albert Einstein College of Medicine, Bronx, NY; Peloton Advantage, LLC, an OPEN Health Company (L.F.), Parsippany, NJ; Global Medical Affairs (A.M.A.), Allergan plc, Irvine, CA; Vedanta Research (K.M.F., M.L.R.), Chapel Hill, NC; and Neurology Research (T.J.S.), Mayo Clinic, Phoenix, AZ
| | - Michael L Reed
- From the Department of Neurology (R.B.L., D.C.B., B.W.F.), Albert Einstein College of Medicine, Bronx, NY; Peloton Advantage, LLC, an OPEN Health Company (L.F.), Parsippany, NJ; Global Medical Affairs (A.M.A.), Allergan plc, Irvine, CA; Vedanta Research (K.M.F., M.L.R.), Chapel Hill, NC; and Neurology Research (T.J.S.), Mayo Clinic, Phoenix, AZ
| | - Todd J Schwedt
- From the Department of Neurology (R.B.L., D.C.B., B.W.F.), Albert Einstein College of Medicine, Bronx, NY; Peloton Advantage, LLC, an OPEN Health Company (L.F.), Parsippany, NJ; Global Medical Affairs (A.M.A.), Allergan plc, Irvine, CA; Vedanta Research (K.M.F., M.L.R.), Chapel Hill, NC; and Neurology Research (T.J.S.), Mayo Clinic, Phoenix, AZ
| |
Collapse
|
5
|
Kudrow D, Munjal S, Bensimon L, Lokhandwala T, Yue B, Coutinho AD, Silberstein SD. Treatment patterns of patients diagnosed with major headache disorders: A retrospective claims analysis. CEPHALALGIA REPORTS 2020. [DOI: 10.1177/2515816320913992] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Objective:To describe patient characteristics, treatment patterns, and health care costs among patients diagnosed with major headache disorders overall and by type (tension-type headache [TTH], migraine, cluster headache [CH], or >1 primary headache type), and secondarily to evaluate drug treatment patterns among triptan initiators with a major headache diagnosis.Methods:Using US claims data from January 2012 through December 2017, we identified adults with evidence of a major headache disorder: TTH, migraine, or CH; the first diagnosis date was deemed the index date. To evaluate triptan use specifically, patients who initiated triptans were identified; the first triptan claim date was deemed the index date. Patient characteristics, treatment patterns (concomitant treatments, adherence, number of fills), and annual health care costs data were obtained.Results:Of the 418,779 patients diagnosed with major headache disorders, the following 4 cohorts were created: TTH (8%), migraine (87%), CH (1%), and >1 primary headache type (4%). The majority used analgesic (54–73%) and psychotropic (57–81%) drugs, primarily opioids (36–53%). Headache-related costs accounted for one-fifth of all-cause costs. Of the 229,946 patients who initiated triptans, the following 7 study cohorts were analyzed: sumatriptan (68%), rizatriptan (21%), eletriptan (5%), zolmitriptan (3%), naratriptan (2%), frovatriptan (1%), and almotriptan (<1%). The major concomitant analgesic medication classes were opioids (41%) and nonsteroidal anti-inflammatory drugs (34%).Conclusion:The primary headache disorder treatment paradigm is complex, with significant variability. Predominant concomitant use of opioids and switching to opioids is of concern, necessitating solutions to minimize opioid use. Switching to non-oral/fast-acting or targeted preventive therapies should be considered.
Collapse
Affiliation(s)
- David Kudrow
- California Medical Clinic for Headache Neurological Research Institute, Santa Monica, CA, USA
| | - Sagar Munjal
- Promius Pharma, A Subsidiary of Dr. Reddy’s Laboratories, Princeton, NJ, USA
| | - Leah Bensimon
- Promius Pharma, A Subsidiary of Dr. Reddy’s Laboratories, Princeton, NJ, USA
| | | | - Binglin Yue
- Real-World Evidence, Xcenda LLC, Palm Harbor, FL, USA
| | | | | |
Collapse
|
6
|
Drinovac Vlah V, Filipović B, Bach-Rojecky L, Lacković Z. Role of central versus peripheral opioid system in antinociceptive and anti-inflammatory effect of botulinum toxin type A in trigeminal region. Eur J Pain 2017; 22:583-591. [PMID: 29134730 DOI: 10.1002/ejp.1146] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/12/2017] [Indexed: 12/12/2022]
Abstract
BACKGROUND Although botulinum toxin type A (BT-A) is approved for chronic migraine treatment, its site and mechanism of action are still elusive. Recently our group discovered that suppression of CGRP release from dural nerve endings might account for antimigraine action of pericranially injected BT-A. We demonstrated that central antinociceptive effect of BT-A in sciatic region involves endogenous opioid system as well. Here we investigated possible interaction of BT-A with endogenous opioid system within the trigeminal region. METHODS In orofacial formalin test we investigated the influence of centrally acting opioid antagonist naltrexone (2 mg/kg, s.c.) versus peripherally acting methylnaltrexone (2 mg/kg, s.c.) on BT-A's (5 U/kg, s.c. into whisker pad) or morphine's (6 mg/kg, s.c.) antinociceptive effect and the effect on dural neurogenic inflammation (DNI). DNI was assessed by Evans blue-plasma protein extravasation. RESULTS Naltrexone abolished the effect of BT-A on pain and dural plasma protein extravasation, whereas peripherally acting methylnaltrexone did not change either BT-A's effect on pain or its effect on dural extravasation. Naltrexone abolished the antinociceptive and anti-inflammatory effects of morphine, as well. However, methylnaltrexone decreased the antinociceptive effect of morphine only partially in the second phase of the test and had no significant effect on morphine-mediated reduction in DNI. CONCLUSIONS Morphine acts on pain in trigeminal region both peripherally and centrally, whereas the effect on dural plasma protein extravasation seems to be only centrally mediated. However, the interaction of BT-A with endogenous opioid system, with consequent inhibition of nociceptive transmission as well as the DNI, occurs primarily centrally. SIGNIFICANCE Botulinum toxin type A (BT-A)'s axonal transport and potential transcytosis suggest that its antinociceptive effect might involve diverse neurotransmitters at different sites of trigeminal system. Here we discovered that the reduction in pain and accompanying DNI involves the interaction of BT-A with central endogenous opioid system (probably at the level of trigeminal nucleus caudalis).
Collapse
Affiliation(s)
- V Drinovac Vlah
- Department of Pharmacology, University of Zagreb Faculty of Pharmacy and Biochemistry, Croatia
| | - B Filipović
- Laboratory of Molecular Neuropharmacology, Department of Pharmacology, University of Zagreb School of Medicine, Croatia.,Department of Otorhinolaryngology & Head and Neck Surgery, University Hospital Sveti Duh, Zagreb, Croatia
| | - L Bach-Rojecky
- Department of Pharmacology, University of Zagreb Faculty of Pharmacy and Biochemistry, Croatia
| | - Z Lacković
- Laboratory of Molecular Neuropharmacology, Department of Pharmacology, University of Zagreb School of Medicine, Croatia
| |
Collapse
|
7
|
Razavi S, Gharaei B, Jafari A, Aghamohammadi H, Mirkheshti A. Propofol and alfentanil in treatment of a patient with episodic cluster headache. Anesth Pain Med 2014; 4:e17560. [PMID: 24910816 PMCID: PMC4030261 DOI: 10.5812/aapm.17560] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2014] [Revised: 02/09/2014] [Accepted: 02/26/2014] [Indexed: 11/24/2022] Open
Abstract
Introduction: Cluster headache is a severe hemifacial pain with concomitant symptoms such as lacrimation, conjunctival congestion, and nasal discharge. Peripheral (to be a spectrum of trigeminal autonomic cephalgia) and central (hypothalamus) disorders have been suggested to be involved. Several modalities have been recommended to prevent or alleviate this devastating headache. Case Presentation: In this case report, we presented a young man with an acute cluster headache who responded dramatically to the treatment with propofol and alfentanil. Conclusions: Propofol and alfentanil combination can be considered as a treatment approach in the attack phase of cluster headache.
Collapse
Affiliation(s)
- Sajjad Razavi
- Anesthesiology Research Center, Mofid Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Babak Gharaei
- Anesthesiology Research Center, Labbafinejad Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Alireza Jafari
- Anesthesiology Research Center, Labbafinejad Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Homayoun Aghamohammadi
- Anesthesiology Research Center, Labbafinejad Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Alireza Mirkheshti
- Anesthesiology Research Center, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
- Corresponding author: Alireza Mirkheshti, Anesthesiology Research Center, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Tel: + 98-2177567840. E-mail:
| |
Collapse
|
8
|
Spinal endomorphin 2 antinociception and the mechanisms that produce it are both sex- and stage of estrus cycle-dependent in rats. THE JOURNAL OF PAIN 2013; 14:1522-30. [PMID: 24084000 DOI: 10.1016/j.jpain.2013.09.002] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/17/2013] [Revised: 09/10/2013] [Accepted: 09/12/2013] [Indexed: 11/23/2022]
Abstract
UNLABELLED Endomorphin 2 (EM2) is the predominant endogenous mu-opioid receptor (MOR) ligand in the spinal cord. Given its endogenous presence, antinociceptive responsiveness to the intrathecal application of EM2 most likely reflects its ability to modulate nociception when released in situ. In order to explore the physiological pliability of sex-dependent differences in spinal MOR-mediated antinociception, we investigated the antinociception produced by intrathecal EM2 in male, proestrus female, and diestrus female rats. Antinociception was reflected by changes in tail flick latency to radiant heat. In females, the spinal EM2 antinociceptive system oscillated between analgesically active and inactive states. During diestrus, when circulating estrogens are low, spinal EM2 antinociceptive responsiveness was minimal. In contrast, during proestrus, when circulating estrogens are high, spinal EM2 antinociception was robust and comparable in magnitude to that manifest by males. Furthermore, in proestrus females, spinal EM2 antinociception required spinal dynorphin and kappa-opioid receptor activation, concomitant with MOR activation. This is required for neither spinal EM2 antinociception in males nor the antinociception elicited in proestrus females by spinal sufentanil or [d-Ala(2),N-methyl-Phe(4),Gly-ol(5)]-enkephalin, which are prototypic MOR-selective nonpeptide and peptide agonists, respectively. These results reveal that spinal EM2 antinociception and the signaling mechanisms used to produce it fundamentally differ in males and females. PERSPECTIVE The inability to mount spinal EM2 antinociception during defined stages of the estrus (and presumably menstrual) cycle and impaired transition from spinal EM2 analgesically nonresponsive to responsive physiological states could be causally associated with the well-documented greater severity and frequency of chronic intractable pain syndromes in women vs men.
Collapse
|